Welcome to our dedicated page for Ashland news (Ticker: ASH), a resource for investors and traders seeking the latest updates and insights on Ashland stock.
Ashland Inc. (NYSE: ASH) is a global leader in specialty chemicals and advanced additives serving industries from pharmaceuticals to sustainable construction. This page provides investors and professionals with essential updates on corporate developments, financial results, and market innovations.
Discover official press releases alongside curated analysis of Ashland's strategic initiatives in life sciences, personal care ingredients, and industrial solutions. Our repository includes updates on product launches, sustainability efforts, and operational milestones that shape the company's trajectory.
Key content categories include quarterly earnings reports, merger and acquisition activity, leadership changes, and technological breakthroughs in specialty chemicals. All materials are sourced from verified channels to ensure accuracy and relevance for decision-makers.
Bookmark this page for streamlined access to Ashland's evolving story. Check regularly for new developments that demonstrate the company's commitment to solving complex material science challenges through innovation.
Ashland (NYSE: ASH) reported Q3 fiscal 2025 results with sales of $463 million, down 15% year-over-year. The company recorded a significant net loss of $742 million, primarily due to a $706 million non-cash goodwill impairment charge.
Key financial metrics include Adjusted EBITDA of $113 million (down 19%) and Adjusted Income from Continuing Operations of $48 million ($1.04 per diluted share). Portfolio Optimization initiatives reduced sales by approximately $53 million or 10%. The company generated $114 million in operating cash flow and $108 million in Ongoing Free Cash Flow.
Ashland narrowed its FY2025 outlook, projecting sales of $1.825-1.850 billion and Adjusted EBITDA of $400-410 million, with expectations weighted toward the lower end of the range due to ongoing market uncertainty.
Ashland (NYSE: ASH) has appointed William C. Whitaker as senior vice president and chief financial officer, effective July 18, 2025. Whitaker, who was serving as interim CFO, has been with Ashland since 2015, holding various leadership positions in corporate development, treasury, financial planning and analysis, and investor relations.
Whitaker brings valuable experience from his previous roles in private equity and transaction advisory services. He holds a Bachelor's degree in Finance from Ohio State University and is a Chartered Financial Analyst (CFA). The appointment was announced by Guillermo Novo, Ashland's chair and CEO, who expressed confidence in Whitaker's leadership abilities.
Ashland (NYSE: ASH) has scheduled its third-quarter fiscal 2025 earnings release for July 29, 2025, at 5 p.m. ET, followed by a live webcast with analysts on July 30, 2025, at 10 a.m. ET.
Key executives participating in the presentation include Guillermo Novo (Chair and CEO), William Whitaker (Interim CFO), Dago Caceres (SVP, Specialty Additives), Alessandra Faccin (SVP, Life Sciences), and Jim Minicucci (SVP, Personal Care). The presentation materials will be available on Ashland's investor relations website, with an archived version accessible for 12 months post-event.
Ashland (NYSE: ASH) announced significant leadership changes in its operations team. Karl Bostaph, senior vice president of operations, will retire on October 1, 2025, after serving since joining Hercules in 1990, which Ashland acquired in 2008.
Wayne Muil, previously global director of operations for specialty additives, has been promoted to senior vice president of operations, effective immediately. Muil, who joined Ashland in 2024, brings over 25 years of experience in manufacturing and supply chain operations, including his role as vice president of manufacturing and engineering at Sadara Chemical Company.
To ensure continuity, Bostaph will serve as a special advisor for operations, working alongside Muil until his retirement to facilitate a seamless transition for customers and internal teams.
Ashland (NYSE: ASH) has provided an update on its $60 million manufacturing network optimization plan, announcing significant facility changes and strategic consolidations. The company will close its Parlin, New Jersey facility and transfer hydroxyethyl cellulose (HEC) production to Hopewell, Virginia. Additionally, Ashland will close its Chatham, New Jersey plant and move microbial protection production to Freetown, Massachusetts.
The optimization plan follows the completion of a $30 million restructuring initiative and includes major investments in facilities across the United States, Europe, China, Brazil, and India. The company is strengthening its core technologies, including vinyl pyrrolidone and derivatives (VP&D) and HEC, while expanding its global manufacturing footprint for injectables, tablet coatings, and biofunctionals businesses.
Ashland (ASH) is hosting an Innovation Day for analysts and investors on May 29, 2025, at their Bridgewater, New Jersey facility. The event will showcase the company's enhanced capabilities and expanded applications of their scalable technology platforms. Key executives, including CEO Guillermo Novo and CTO Osama Musa, will present detailed insights on platform developments and commercial opportunities across Life Sciences, Personal Care, and Specialty Additives segments.
The event runs from 9:00 AM to 11:30 AM ET, featuring presentations and a Q&A session. In-person attendees will also enjoy a luncheon and lab tour until 2:00 PM ET. The event will be available via live webcast, with materials and replay accessible on Ashland's investor website for 12 months.
Valvoline (NYSE: VVV) has appointed Kevin Willis as its new Chief Financial Officer, effective May 19, 2025. Willis succeeds Mary Meixelsperger, who announced her planned retirement in October 2024. Willis joins Valvoline with extensive public company experience, having served as CFO of Ashland Inc. (NYSE: ASH) since 2013. He played a key role in Valvoline's 2016 IPO separation from Ashland and has significant expertise in capital markets management and financial systems integrations. Willis holds a BBA in accounting from Eastern Kentucky University and an MBA from Northwestern University's Kellogg School of Management. Meixelsperger will remain with the company through a transition period.
Ashland (NYSE: ASH) has announced its board of directors has declared a quarterly cash dividend of $0.415 per share, marking a 2.5% increase from the previous quarter. The dividend will be paid on June 15, 2025, to stockholders of record as of June 1, 2025. As of April 30, 2025, Ashland reported 45,696,225 outstanding shares of common stock.
Ashland Inc. (NYSE: ASH) announced significant executive leadership changes. Kevin Willis, senior vice president and CFO, will depart on May 16, 2025, after a 38-year tenure with the company. The board appointed William C. Whitaker, current vice president of finance and director of investor relations, as interim CFO. Additionally, Samuel A. Richardson was appointed as vice president, controller and principal accounting officer.
Whitaker, 36, has been with Ashland since 2015, holding various positions in corporate development, treasury, FP&A, and investor relations. Richardson, 46, has served as controller since January 2020 and has extensive accounting experience with the company since 2008.
Ashland reported second quarter fiscal 2025 results with sales of $479 million, down 17% year-over-year. The decline includes a 12% reduction from Portfolio Optimization initiatives and a 5% organic decrease.
Key financial metrics include:
- Income from continuing operations: $30 million ($0.63 per diluted share)
- Net income: $31 million ($0.65 per diluted share)
- Adjusted EBITDA: $108 million, down 14% from prior year
- Operating cash flow: $9 million
The company's segments showed mixed performance: Life Sciences sales fell 23% to $172 million, Personal Care decreased 14% to $146 million, Specialty Additives declined 15% to $134 million, and Intermediates dropped 8% to $37 million. Despite challenges, cost savings initiatives are on track, with Life Sciences and Personal Care maintaining EBITDA margins above 30%. The company has revised its full-year fiscal 2025 outlook due to weakening macroeconomic conditions.
FAQ
What is the current stock price of Ashland (ASH)?
What is the market cap of Ashland (ASH)?
